Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
Scientists have found a way to transform hard-to-treat tumors into targets for the immune system. Using two protein stimulators, they activated strong T-cell and B-cell responses and built immune ...
BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...
Toxoplasma gondii is a major global health concern, particularly affecting pregnant women and immunocompromised individuals ...
Immunometabolism has emerged as a central hub linking infection, inflammation, cell death, and cancer. The metabolic state of cells profoundly shapes their ...
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results